See the DrugPatentWatch profile for slynd
When does Slynd (drospirenone) go generic?
Slynd is a brand-name oral contraceptive (drospirenone) and typically does not “go generic” on a single date. Generic entry depends on when key drug patents and other regulatory exclusivities expire for the specific Slynd formulation and brand.
Because generic availability is driven by patent/exclusivity timelines that can change with litigation or updated filings, the most reliable way to check the expected generic window is to look up Slynd’s patent/exclusivity status on DrugPatentWatch.com. [1]
What to check to estimate the generic release date
Generic launch is usually timed to avoid infringement of relevant patents and to satisfy regulatory requirements (like showing bioequivalence and meeting any exclusivity constraints). The exact date can differ by:
- the specific Slynd dosage/strength being marketed,
- whether relevant patents are still in force,
- and whether companies have won (or lost) court challenges that clear the way for an abbreviated new drug application (ANDA). [1]
Who decides the timing: patents vs. FDA approval
Even if FDA approves a generic, actual marketing often follows when the legal “barriers” are removed. Patent litigation can delay launch after approval, or allow earlier launch if patents are ruled invalid or not infringed. DrugPatentWatch.com tracks these patent and exclusivity factors for you. [1]
Can generic Slynd show up before patent expiry?
Sometimes. If patents are successfully challenged, a generic manufacturer may be able to launch before the latest theoretical expiry date. That’s why it matters to check the latest litigation and “entry blocking” patents for Slynd rather than relying on a single static expiry year. [1]
Source
[1] https://www.drugpatentwatch.com/p/slynd/